Risk Factors for Acute Kidney Injury Induced by Intravenous Polymyxin B in Chinese Patients with Severe Infection

被引:4
作者
Jia, Xuedong [1 ,2 ]
Guo, Cuohui [1 ]
Yin, Zhao [1 ,2 ]
Zhang, Wan [1 ,2 ]
Du, Shuzhang [1 ,2 ]
Zhang, Xiaojian [1 ,2 ]
机构
[1] Zhengzhou Univ, Dept Pharm, Affiliated Hosp 1, Zhengzhou, Peoples R China
[2] Precis Clin Pharm Key Lab Henan Prov, Zhengzhou, Peoples R China
关键词
polymyxin B; acute kidney injury; risk factors; anti-infective therapy; NEPHROTOXICITY; COLISTIMETHATE;
D O I
10.2147/IDR.S363944
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Purpose: To analyze the risk factors for acute kidney injury (AKI) induced by intravenous polymyxin B in Chinese patients with severe infection and to provide a reference for clinicians and pharmacists. Methods: We retrospectively analyzed patients treated with intravenous polymyxin B from August 2018 to August 2020 in a Chinese teaching hospital. Renal function was evaluated during therapy with polymyxin B and at the end of the treatment. Univariate and multivariate analyses were conducted to determine risk factors for the nephrotoxicity of polymyxin B. Results: A total of 321 patients were included, and the incidence of AKI was 26.2% and 25.1% during polymyxin B therapy and at the end of treatment, respectively. Independent risk factors for AKI during therapy with polymyxin B were septic shock, coadministration of vancomycin or loop diuretics, and advanced age (>= 60 years), while the incidence of AKI during treatment with polymyxin B was considered to be an independent risk factor for AKI at the end of the treatment. Conclusion: Septic shock, coadministration of vancomycin or loop diuretics, and advanced age (age >= 60 years) were found to be risk factors for AKI induced by intravenous polymyxin B. Clinicians and pharmacists should consider these factors when designing and recommending treatment with polymyxin B.
引用
收藏
页码:1957 / 1965
页数:9
相关论文
共 34 条
[1]   Higher Incidence of Acute Kidney Injury With Intravenous Colistimethate Sodium Compared With Polymyxin B in Critically Ill Patients at a Tertiary Care Medical Center [J].
Akajagbor, Darowan S. ;
Wilson, Sharon L. ;
Shere-Wolfe, Kapana D. ;
Dakum, Paul ;
Charurat, Manhattan E. ;
Gilliam, Bruce L. .
CLINICAL INFECTIOUS DISEASES, 2013, 57 (09) :1300-1303
[2]   Acute kidney injury and vancomycin/piperacillin/tazobactam in adult patients: a systematic review [J].
Ciarambino, Tiziana ;
Giannico, Orazio Valerio ;
Campanile, Amalia ;
Tirelli, Paolo ;
Para, Ombretta ;
Signoriello, Giuseppe ;
Giordano, Mauro .
INTERNAL AND EMERGENCY MEDICINE, 2020, 15 (02) :327-331
[3]  
Doshi NM, 2011, PHARMACOTHERAPY, V31, P1257, DOI 10.1592/phco.31.12.1257
[4]   Risk factors for nephrotoxicity onset associated with polymyxin B therapy [J].
Dubrovskaya, Yanina ;
Prasad, Nishant ;
Lee, Yuman ;
Esaian, Diana ;
Figueroa, Deborah A. ;
Tam, Vincent H. .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2015, 70 (06) :1903-1907
[5]   The impact of polymyxin B dosage on in-hospital mortality of patients treated with this antibiotic [J].
Elias, Laura S. ;
Konzen, Daniele ;
Krebs, Juliana M. ;
Zavascki, Alexandre P. .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2010, 65 (10) :2231-2237
[6]   Clinical use of intravenous polymyxin B for the treatment of patients with multidrug-resistant Gram-negative bacterial infections: An evaluation of the current evidence [J].
Falagas, Matthew E. ;
Kyriakidou, Margarita ;
Voulgaris, Georgios L. ;
Vokos, Filippos ;
Politi, Sevasti ;
Kechagias, Konstantinos S. .
JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE, 2021, 24 :342-359
[7]   Impact of polymyxin-B-associated acute kidney injury in 1-year mortality and renal function recovery [J].
Gomes, Eduardo C. ;
Falci, Diego R. ;
Bergo, Pedro ;
Zavascki, Alexandre P. ;
Rigatto, Maria Helena .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2018, 52 (01) :86-89
[8]  
Kalil AC, 2016, CLIN INFECT DIS, V63, P575, DOI [10.1093/cid/ciw504, 10.1093/cid/ciw353]
[9]   Reviving Polymyxins: Achievements, Lessons and the Road Ahead [J].
Li, Jian .
POLYMYXIN ANTIBIOTICS: FROM LABORATORY BENCH TO BEDSIDE, 2019, 1145 :1-8
[10]   Carbapenem-Resistant Enterobacterales, Carbapenem Resistant Organisms, Carbapenemase-Producing Enterobacterales, and Carbapenemase-Producing Organisms: Terminology Past its "Sell-By Date" in an Era of New Antibiotics and Regional Carbapenemase Epidemiology [J].
Livermore, David M. ;
Nicolau, David P. ;
Hopkins, Katie L. ;
Meunier, Daniele .
CLINICAL INFECTIOUS DISEASES, 2020, 71 (07) :1776-1782